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shortage of available and suitable donors.2 Additionally,
because the lung is more susceptible than other organs
to antemortem deterioration, even fewer lungs are avail-
able from the already limited number of human donors.
One approach to extending transplantation as a therapy
to all who need it is to use animals in lieu of human
beings as a source of lungs, that is, xenotransplantation.
The major hurdle to clinical xenotransplantation is
the severe immune reaction of the recipient against the
graft. This reaction as it occurs in the xenografted heart
and kidney has been extensively studied in recent years.
To a certain extent, these studies have elucidated the
pathogenesis of xenograft rejection at a molecular level
and, as a result, have led to the development of incisive
therapies.3-6 Thus, although some have speculated that
clinical trials of heart and kidney xenografts might be in
the offing, the current status of pulmonary xenotrans-
plantation is less certain. Although pulmonary
xenografts undergo functional deterioration and tissue
injury at a tempo similar to that of rejection of cardiac
and renal xenografts, the events leading to primary fail-
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ure of lung xenotransplants are less certain.
Complement has been shown to be important in acute
lung dysfunction and injury. However, even when
known defects in regulation of heterologous comple-
ment activation are corrected, a residual dysfunction
remains in swine-to-primate lung transplants.7
Xenoreactive antibodies might play a role in this lung
xenograft failure resulting from residual dysfunc-
tion.8-10 The goal of this article is to address the role of
antibodies in residual lung xenograft dysfunction in an
orthotopic pig-to-primate model.
Materials and methods
Animal care conformed to the standards of the National
Society for Medical Research (“Principles of Laboratory
Animal Care”) and “The Guide for the Care and Use of
Laboratory Animals” (NIH publication No. 86-23, revised
1985). Experiments were approved by the Duke University
Institutional Animal Care and Use Committee.
Donor operation.  Adult swine (15-20 kg) transgenic for
human decay accelerating factor (hDAF) and CD59 were
supplied by Nextran, Princeton, New Jersey. The constructs
used in the generation of  these swine contain a mouse H-2Kb
promoter, regulating expression of complementary DNA for
hDAF, and a chick β-actin promoter controlling expression of
a complementary DNA for human CD59.11
Animals were anesthetized with intramuscular administra-
tion of ketamine hydrochloride (20 mg/kg) and intravenous
fentanyl (100 µg/kg). Endotracheal intubation and ventilation
were established with 100% oxygen. All swine received
methylprednisolone (8 mg/kg) and indomethacin (INN:
indometacin) (1 mg/kg) 1 hour before harvest. The harvest
procedure was performed as previously described.9
Alprostadil (prostaglandin E1) (50 µg/kg) was injected direct-
ly into the pulmonary artery, and heparin was administered
intravenously (500 U/kg) 10 minutes before harvest.
Modified Euro-Collins solution containing heparin (10
U/mL), papaverine hydrochloride (0.1 mg/mL), methylpred-
nisolone (1 mg/mL), indomethacin (0.1 mg/mL), and
nicardipine (0.2 mg/mL) (Wyeth Laboratories Inc,
Philadelphia, Pa) was administered into the pulmonary artery
from a height of 30 cm (25 mL/kg) for pulmonary preserva-
tion. The heart and lungs were then removed en bloc and
immersed in cold (4°C) saline solution.
Kidney harvest/ex vivo perfusion (Fig 1). Baboons
underwent immunodepletion by ex vivo swine kidney perfu-
sion (n = 3). Pigs used as kidney donors were hDAF/CD59.
The harvest technique has been described previously.12 For
each baboon (n = 3), intravenous cannulas were placed in the
femoral artery and femoral vein under direct visualization,
and after heparinization (1000 U/kg) they were connected to
the renal artery and vein, respectively, of 4 swine kidneys.
Each kidney was perfused for 30 minutes with only 1 kidney
at a time being perfused (ie, in sequence). A flow probe was
not used to assess perfusion through the kidneys.
Depletion of immunoglobulin (Fig 1). Immunoglobulin
depletion was accomplished by separating plasma and pass-
ing it though anti-immunoglobulin columns (Therabsorb;
Unterschleisshein, Germany) as previously described.4 With
the baboons under general anesthesia, a splenectomy was
performed and a double-lumen Hickman catheter (Bard
Access Systems, Salt Lake City, Utah) was placed in the
internal jugular veins. Immunoglobulin depletion was then
performed 5 days before transplantation and on the morning
of transplantation. Each treatment consisted of 8 to 12 cycles
equaling approximately 3 to 5 plasma volumes. The animals
were heparinized (1000 U/kg) for each column treatment.
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Fig 1. Schematic of pretransplantation antibody removal technique. This study comprised 4 groups. The control
group consisted of transgenic swine lung transplants into unmodified baboons. Ig, Immunoglobulin. 
Pretransplantation extracorporeal pulmonary perfu-
sion (Fig 1). Baboons underwent immunodepletion by ex
vivo lung perfusion (n = 3) by the method previously
described.9 All swine used as ex vivo lung donors were
hDAF/CD59 transgenic animals. Baboons were heparinized
before perfusion (1000 U/kg).
Pulmonary transplantation. Baboons (12-16 kg) were
sedated with ketamine hydrochloride (10 mg/kg), intubated,
and their lungs were ventilated with an adult volume-con-
trolled ventilator (Bennett Respiration Products, Inc, Santa
Monica, Calif) with 100% oxygen at a rate of 10 breaths/min
with a tidal volume of 12 mL/kg. All baboons underwent left
pneumonectomy followed by heparinization (1000 U/kg) and
orthotopic swine lung transplantation as described previously.9
Immunosuppression. Baboons undergoing column
absorption as the method of antibody depletion were
immunosuppressed beginning the first day of antibody deple-
tion (day –5). The immunosuppressive regimen consisted of
methylprednisolone (10 mg/kg per day tapered by 1 mg/kg
per day, cyclosporine (5 mg/kg per day after a loading dose
of 15 mg/kg), and cyclophosphamide (1-5 mg/kg per day
after a loading dose of 10 mg/kg per day for 2 to 3 days).3,4
Baboons undergoing kidney or lung perfusion as the
method of antibody depletion received methylprednisolone
(Solu-Medrol; 8 mg/kg), cyclosporine (10-15 mg/kg), and
azathioprine (Imuran; 2 mg/kg) on the morning of the
experiment.
Data acquisition. Pulmonary artery flow and cardiac out-
put were measured with an ultrasonic flowmeter (Transonics
Systems Inc, Ithaca, NY), and pulmonary artery pressure was
determined with a Millar Mikro-Tip micromanometer (Millar
Instruments, Inc, Houston, Tex) positioned in the proximal
main pulmonary artery.
Analysis of tissue biopsy specimens. Biopsy specimens for
hematoxylin and eosin staining were taken from varying
areas of the lung and fixed in 10% buffered formalin for
greater than 24 hours. After treatment with formalin, the sam-
ples were dehydrated and embedded in paraffin. The embed-
ded samples were cut into 4-µm thick sections, rehydrated,
and stained with hematoxylin and eosin.
For immunohistochemical studies, samples were obtained,
frozen, sectioned, and fixed as previously described.4
Sections from each sample were incubated with affinity-iso-
lated fluorescein isothiocyanate (FITC)-conjugated goat anti-
human immunoglobulin (Ig) M (µ-chain specific; Kirkegaard
& Perry Laboratories, Inc, Gaithersburg, Md); affinity-isolat-
ed, FITC-conjugated goat anti-human IgG (γ-chain specific;
Kirkegaard & Perry Laboratories, Inc); affinity-isolated,
FITC-conjugated goat anti-human C3 (Organon Teknika-
Cappel, Durham, NC); affinity-isolated, FITC-conjugated
goat anti-human C4 (Organon Teknika-Cappel); affinity-iso-
lated, FITC-conjugated rabbit anti-human fibrinogen
(Accurate Chemical and Scientific Corp, Westbury, NY);
murine monoclonal antibody against human C5b neoantigen
(Quidel, San Diego, Calif); or murine monoclonal antibody
against a neoantigen of the membrane attack complex
(MBM5; generously provided by A. F. Michael, University of
Minnesota,13 as previously described14). Tissue sections were
then washed with phosphate-buffered saline solution.
Unlabeled murine monoclonal antibodies were detected with
a double fluorochrome antibody layer consisting of affinity-
isolated, F(ab´)2 FITC-conjugated goat anti-mouse IgG and
affinity-isolated F(ab´)2 FITC-conjugated rabbit anti-goat
IgG (Organon Teknika-Cappel). After the staining proce-
dures, tissue sections were washed with phosphate-buffered
saline solution and mounted with p-phenylenediamine/glyc-
erol solution.14 All anti-human reagents were shown to cross
react with their baboon counterparts. Background immuno-
fluorescence was assessed by omitting the primary antibod-
ies. The tissue samples were studied with a Leitz DMRB epi-
fluorescence microscope (Leitz, Wetzlar, Germany).
Quantitation of total IgM and IgG. Total immunoglobulin
levels were determined by an enzyme-linked immunosorbent
assay with the use of affinity-purified alkaline phos-
phatase–conjugated goat antibodies specific for human µ-
chain or γ-chain (Sigma Chemical Co, St Louis, Mo), as pre-
viously described.4 The assays were carried out at room
temperature and the absorbance at 405 nm was determined
with an EL 340 Bio Kinetics Reader (Bio Kinetics Corp, San
Antonio, Tex).
Quantitation of xenoreactive IgM and anti-galactose
α(1,3) galactosyl (anti-Galα[1,3]Gal) antibody levels. The
levels of xenoreactive antibodies present in the serum or plas-
ma samples taken during the experiment were determined on
the basis of binding to cultured porcine aortic endothelial
cells, as described previously.15 Comparison with serum con-
taining known levels of anti-Galα(1,3)Gal IgM was made to
determine absolute levels.16,17
Statistical analysis. Values are reported as mean ± SEM
and analyzed by 1-way analysis of variance with comparisons
between the groups made with the Student-Newman-Keuls
test. Data were analyzed with Glantz’s primer of biostatistics
computer software (version 4.02, McGraw-Hill, 1996).
Termination of experiments. Per protocol, these studies
were terminated at 24 hours or sooner if graft flow was less
than 50 mL/min for 2 consecutive hours.
Results
Four lungs from swine expressing hDAF and human
CD59 were transplanted into baboons. Results previ-
ously reported have showed that 1-hour blood flow
though these transgenic lungs was 12-fold (317.5 ±
61.4 mL/min) the rate through unmodified swine lungs
(26.7 ± 12.1 mL/min). However, blood flow was still
only 22% of the cardiac output. Immunohistochemical
staining of the lung tissues did not show significant
deposition of IgM, C3, C4, and membrane attack com-
plex within the graft microvasculature. In lung trans-
plants performed with outbred swine as donors, early
pulmonary edema and microvascular thrombosis were
seen. Among the 4 transgenic swine lungs expressing
hDAF and CD59, 2 had moderately severe pulmonary
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 1
Lau et al   31
edema associated with alveolar wall disruption and all
4 had fibrin plugs apparent at 180 minutes. These
results have been reported previously.7
To test whether the residual defect in pulmonary
function in transgenic lungs was caused by xenoreac-
tive antibodies, we assessed whether depletion of
xenoreactive natural antibodies would prevent physio-
logic and pathologic deterioration of the lung
xenografts. Xenoreactive antibody depletion was
accomplished by perfusion of blood of the baboon
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Fig 2A.  Blood was obtained from each baboon recipient after pretransplantation antibody depletion (by perfusion
through porcine kidneys [A], Ig-depleting column [B], or porcine lungs [C]) and after transplantation of a trans-
genic porcine lung expressing human decay accelerating factor (hDAF) and CD59. The level of anti-Galα(1-3)Gal
IgM was measured by enzyme-linked immunosorbent assay on cultured porcine endothelial cells from the binding
eliminated by treatment of the cells with α-galactosidase. Absolute concentrations were determined after compar-
ison with a referenced standard. Time 0 refers to the time of transplantation. The group undergoing pretransplan-
tation antibody depletion by Ig-depleting column underwent two separate column treatments (day –5 and day 0)
with a rebound seen after the first treatment. The difference in remaining anti-Galα(1-3)Gal antibodies after each
pretransplantation depletion technique was not significant between the treated groups.
Fig 2B.  The total IgM (1) and IgG (2) antibodies remaining after pretransplantation antibody depletion by kidneys,
total immunoglobulin-depleting columns, or lungs as measured by enzyme-linked immunosorbent assay. After pre-
transplantation perfusion with either kidneys or lungs, total immunoglobulin in the serum was modestly lower than




through 4 pig kidneys, and the results are shown in Figs
2A and 2B. The degree of baboon complement,
platelet, and white blood cell (WBC) depletion by ex
vivo kidney perfusion is shown in Figs 3 and 4. As
shown in Fig 5, A, not only did depletion of xenoreac-
tive antibodies by perfusion of porcine kidneys fail to
improve blood flow in the transplanted transgenic
swine lung, it seemingly worsened flow, with graft
flows at 1 hour only 50% of graft flows in transgenic
swine not undergoing depletion of xenoreactive anti-
bodies. Immunohistochemical staining of biopsy spec-
imens from the transgenic swine lung transplanted into
baboons after undergoing xenoreactive natural anti-
body depletion by perfusion with swine kidneys failed
to show significant deposition of IgM, C3, C4, and
membrane attack complex within the graft microvascu-
lature and only trace deposition in the larger pulmonary
arteries. In contrast, in the transgenic porcine kidneys
used to deplete xenoreactive antibodies, IgM, C3, C4,
and membrane attack complex deposition was strongly
positive (Fig 6). Histopathologic examination of the ex
vivo perfused kidneys revealed microvascular thrombi
and edema (Fig 7, A). The 1-hour post-transplantation
lung biopsy specimens from the group with pretrans-
plantation kidney depletion were relatively unremark-
able (Fig 7, B), but by the time of death of the baboons
(24 hours) the microscopic appearance of the lungs was
significant for increased cellularity, hemorrhage,
microvascular thrombosis, and edema (Fig 7, C).
We wished to test whether depletion of xenoreactive
antibodies by pretransplantation kidney perfusion might
have failed to remove certain immunoglobulins specifi-
cally directed against the pulmonary vasculature from
the circulation of the baboons. Therefore, we performed
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Fig 3. Percentage of total C3 (A) and C4 (B) levels remaining after each depletion technique. There was not an
appreciable difference in remaining total complement levels between treated groups.
A B
Fig 4.  Percent of total number of platelets or WBCs remaining after each depletion technique for each animal. Note
that ex vivo lung perfusion results in substantially more depletion of platelets and WBCs than the other techniques.
a series of experiments in which blood from baboons
was depleted of all immunoglobulins by passage of plas-
ma through columns bearing anti-human immunoglobu-
lin antibodies as recently described.4 IgM specific for
Galα(1,3)Gal and total IgM and IgG antibody remaining
after column depletion are shown in Figs 2A and 2B.
Depletion of total IgM and IgG to less than 20% (6.3%-
9.6% IgM; 7.9%-18.5% IgG) was achieved. The degree
of baboon complement, platelet, and WBC depletion by
pretransplantation column perfusion is shown in Figs 3
and 4. Despite effective depletion of the immunoglobu-
lins, the porcine pulmonary xenografts had flows at 60
minutes that were 6.3% of transgenic swine lungs trans-
planted in unmodified baboons (Fig 5, A). The porcine
lungs transplanted into immunoglobulin-depleted
baboons had extensive microvascular thrombi through-
out all lung fields at 60 minutes (Fig 7, D).
To further define the role of xenoreactive antibodies
in pulmonary xenograft dysfunction, we performed a
series of experiments in which blood from baboons
was depleted of xenoreactive antibodies by perfusion
through pig lungs. Presumably, perfusion of the
porcine lungs allowed removal of conventional xenore-
active antibodies and antibodies specific for the lung.
Anti-Galα(1-3)Gal xenoreactive antibodies were
depleted (Fig 2A) after perfusion with swine lungs
while total IgM and IgG only were moderately reduced
(Fig 2B). The degree of baboon complement, platelet,
and WBC depletion by ex vivo lung perfusion is shown
in Figs 3 and 4. As seen in Fig 5, only pretransplanta-
tion lung perfusion significantly improved pulmonary
xenograft flows, with a 175% increase in graft flow at
60 minutes compared with transgenic lungs transplant-
ed into unmanipulated baboons. There was minimal if
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Fig 5.  Physiologic variables of pulmonary xenografts. Measurements were made after the recipient’s blood
pressure and heart rate had stabilized, between 15 and 60 minutes after reperfusion. ‡P < .05 between control
and lung group; §P < .05 between lung and anti-immunoglobulin column groups and between lung and kid-
ney groups. A, Lung xenograft flows. B, Pulmonary vascular resistance (PVR) across xenograft.
A
B
any deposition of IgM, IgG, C3, or C4 in the pul-
monary microvasculature of the ex vivo (Fig 6) or the
transplanted lung. At 120 minutes, the ex vivo lung was
notable for the presence of edema, hemorrhage, and
increased cellularity (Fig 7, E). In contrast, the archi-
tecture of the transplanted lung remained fairly normal
throughout the experiment (24 hours) (Fig 7, F and G).
Discussion
A porcine organ transplanted into an unmodified pri-
mate is subjected to hyperacute rejection. In heart and
kidney xenotransplantation, inhibition of complement
activation successfully prevents hyperacute rejection,
leading to the next phase, acute vascular rejection,
which occurs in the time frame of days. Removal of
antibodies prevents acute vascular rejection in these
organs.4 In lung xenografts, the early dysfunction that
appears similar in time frame to the hyperacute rejec-
tion of other xenografts is only partially abrogated by
complement control.
Work by Daggett,9 Pierson,8 Macchiarini,10 and their
associates has suggested that antibodies play a role in
acute xenograft lung dysfunction in both an in vivo and
an ex vivo pig-to-primate model. Daggett and col-
leagues9 found removal of xenoreactive antibodies of
the baboon by pretransplantation perfusion with a
swine lung resulted in improved hemodynamic vari-
ables and graft survival. Pierson and colleagues8 used
an ex vivo lung perfusion model in which human blood
was perfused through a pig heart-lung block.
Pulmonary vascular resistance increased and pul-
monary edema developed rapidly with a median time to
graft failure of 20 minutes. In that model, thermal inac-
tivation of complement did not prevent the rise in pul-
monary vascular resistance. Absorption of xenoreactive
antibodies did prevent the rise in pulmonary vascular
resistance, but only the combination of heat inactiva-
tion of complement and absorption of xenoreactive
antibodies prolonged graft survival to that achieved
with autologous perfusion.
Macchiarini and colleagues10 reported similar findings
to our data presented here, but in an ex vivo model. In
their study they perfused whole human blood through
swine lungs, livers, or spleens before ex vivo perfusion
of the blood through a swine lung. They also perfused
swine lungs with human plasma that had been depleted
of anti-Gal antibodies by in vitro column immunoab-
sorption of the antibodies. Only swine lung perfusion of
human blood before ex vivo perfusion of another swine
lung resulted in improved functional and histologic sur-
vival of the ex vivo lung. Western blot analysis of plas-
ma samples showed that prior swine lung perfusion
removed antibodies against non-anti-Gal proteins of low
molecular weight that were not eliminated by the anti-
Gal columns. Their conclusions suggested that non-anti-
Gal antibodies removed only by prior swine lung perfu-
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Fig 6.  Deposition of IgM and IgG in pretransplantation-perfused porcine lungs or kidneys. Biopsy specimens from
these pretransplantation-perfused organs were analyzed by immunofluorescence microscopy for deposition of IgM
and IgG. A, IgM. B, IgG. Pretransplantation lung perfusion at end showing no detection of IgM and only trace IgG
in microvasculature of lung. IgG deposition was mostly interstitial, suggesting nonspecific deposition in pretrans-
plantation lung. C, IgM. D, IgG. Pretransplantation kidney perfusion at end showing prominent deposition of both
along the endothelial lining of blood vessels in the pretransplantation kidneys.
sion but not by liver, spleen, or column perfusion were
the cause of improved survival of the ex vivo lungs.
Our data presented in this article support the value of
preperfusion with a swine lung in lung graft survival,
but our findings of worsening graft function with a sig-
nificant reduction in total antibody levels by the anti-
immunoglobulin columns are unexpected based on the
data reported by Macchiarini and colleagues.10 Further
evidence that preperfusion with swine lungs before
swine lung transplantation is not beneficial because of
removal of other non anti-Gal antibodies comes from
our data in which we have looked for and have been
unable to identify unique antigens on porcine pul-
monary microvascular endothelial cells.18,19
Therefore, an important question emerging from our
studies is the mechanism by which perfusion of the
porcine lung confers a protective effect on subsequent
lung xenografts. Depletion of circulating factors other
than xenoreactive antibodies does occur with ex vivo
lung perfusion. In addition to depleting xenoreactive
antibodies, additional factors including platelets and
WBCs are depleted when baboon blood is perfused
through swine lungs. Platelets and WBCs have been
shown by Pierson to play a role in pulmonary xenograft
dysfunction in an ex vivo lung perfusion circuit
(Pierson RN, personal communication). We have
shown that swine von Willebrand factor is shed by
lungs during perfusion with primate blood but not by
kidneys (Platt JL, unpublished data). Swine von
Willebrand factor in contrast to primate von Willebrand
factor is capable of aggregating primate platelets in the
absence of a cofactor or high shear stress.20 The throm-
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Fig 7. Histopathologic features in pretransplantation antibody depletion experiments. A to C, Pretransplantation kid-
ney depletion experiments showing extensive microvascular thrombi and edema in ex vivo kidney (A), relatively
unremarkable post-transplantation 1-hour biopsy (B), but increasing hemorrhage, cellularity, and edema with
increasing time of transplantation (24 hours) (C). D, Extensive microvascular thrombi in 1-hour post-transplantation
lung xenograft biopsy after pretransplantation treatment of baboon with total immunoglobulin-depleting column. 
A B
C D
bocytopenia occurring after lung perfusion may be the
result of deposition of platelets (as a consequence of
von Willebrand factor release) in the ex vivo organ,
resulting in subsequent protection of the lung xenograft
from platelet thrombi. Since swine von Willebrand fac-
tor is not released in substantial quantities with perfu-
sion of swine kidneys, this protective effect (via
platelet removal) is not appreciated. Swine von
Willebrand factor would still be released by the trans-
planted lung, but the microvascular thrombi would be
less in the preperfused swine lung group because of
thrombocytopenia.
Although this discussion may explain why the
xenografts transplanted into baboons after ex vivo lung
perfusion have better function than the xenografts
transplanted into unmodified baboons, it may be more
difficult to explain why xenografts transplanted into
baboons after ex vivo kidney perfusion or treatment
with anti-immunoglobulin column have worse function
than the xenografts transplanted into unmodified
baboons. It is possible that the ex vivo swine kidney
perfusion and anti-immunoglobulin column treatment
of baboons removes protective factors or causes release
of factors detrimental to the swine lung xenograft (but
not to kidney or heart xenografts). For example, it has
been proposed that the lung xenograft is more sensitive
to small amounts of C3a and C5a (Platt JL, unpub-
lished data)21 and thromboxane A2,22 which may be
released during ex vivo kidney perfusion or column
absorption. Further studies are needed to test whether
specific antibody depletion techniques are more toxic
to lung xenografts. The severe microvascular thrombo-
sis seen in the group treated with anti-immunoglobulin
depleting column may be explained by the depletion of
various anticoagulant proteins shifting the environment
to a more procoagulant one.
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Fig 7. Cont’d. With the pretransplantation ex vivo lung after 120 minutes of perfusion with baboon blood, the pres-
ence of edema, hemorrhage, and increased cellularity is noted (E), but the architecture of the transplanted lung
remains fairly normal at 1-hour biopsy and throughout the experiment lasting 24 hours (F and G).
E F
G
Swine von Willebrand factor is known to have
Galα(1,3)Gal epitopes and has been shown to bind
anti-Galα(1,3)Gal antibody.23 We have preliminary evi-
dence that binding of anti-Galα(1,3)Gal antibodies to
swine von Willebrand factor inhibits its ability to
aggregate human platelets to a modest degree (Posther
KE, unpublished data). Therefore, it is possible that
pretransplantation removal of antibodies in association
with release of substantial swine von Willebrand factor
from the lung xenograft results in accelerated
microvascular thrombosis in the transplant. When
unmodified baboons undergo swine lung transplants,
the swine von Willebrand factor that is released com-
plexes with anti-Gal antibodies, and its ability to
aggregate primate platelets is modestly decreased,
resulting in slightly improved function of the grafts.
In conclusion, the pathogenesis of pulmonary injury
in swine-to-primate transplant model is different from
that of heart and kidney. Antibody plays a complex role
in acute injury of pulmonary xenografts. Removal of
antibodies alone before transplantation does not appear
to be beneficial and may actually be detrimental to the
lung xenograft. Although pretransplantation lung per-
fusion depletes xenoreactive antibodies, additional fac-
tors including WBCs and platelets are depleted, which
may explain the protective effect on the pulmonary
xenograft. Although pretransplantation lung perfusion
removes xenoreactive antibodies, additional factors
including WBCs and platelets are also depleted. The
depletion of these additional factors may explain the
protective effect of pretransplantation lung perfusion
on the lung xenograft.
We are indebted to George Quick, Kurt Campbell, Ronnie
Johnson, and Robert McCall for their assistance during oper-
ative procedures.
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